PARICALCITOL

SynDRA canonical compound SYN0023093 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	PTH \| VDR
Mechanism of action	vitamin D receptor agonist
Indication	chronic kidney disease (CKD) \| hyperthyroidism
Disease area	endocrinology \| nephrology

All known targets

zemplar
paricalcitol-d6
COMPOUND-49510
Zemplar
Paracalcin
Abbott brand of paricalcitol
Paricalcitol [USAN]
Ab 122358
ABT-358
Zemplar (TN)
Paricalcitol (USAN/INN)
Paricalcitol, 19-nor-(OH)2-vitD2, paracalcin
(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
(1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol
(1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol
(7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol
19-Nor-1,25-(OH)2D2
19-Nor-1-alpha,25-dihydroxyvitamin D2
19-Nor-1alpha,25-dihydroxyvitamin D2
19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol,(1alpha,3beta,7E,22E)
Compound-49510
CHEBI:7931
6702D36OG5
NCGC00182706-01
(1R,3R)-5-(2-((1R,3aS,7aR,E)-1-((2R,5S,E)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)cyclohexane-1,3-diol
HSDB 7360
Paricalcitol [USAN:USP:INN]
UNII-6702D36OG5
PARICALCITOL [MI]
PARICALCITOL [JAN]
PARICALCITOL [HSDB]
SCHEMBL3655
PARICALCITOL [VANDF]
PARICALCITOL [MART.]
BIDD:GT0330
PARICALCITOL [USP-RS]
PARICALCITOL [WHO-DD]
Paricalcitol (JAN/USP/INN)